Ironwood 10-Q Corrects Q3 Operating Cash Flow to $67.4M From $130.8M
IRWD has more than doubled off its 52-week low of $1.875 on elevated volume (2.6× avg).
Summary
Ironwood's Q3 10-Q confirms the results already released this morning but corrects quarterly operating cash flow to $67.4 million from the $130.8 million first reported, and discloses a new Alkem patent suit over LINZESS generics.
Key Events · Earnings and Guidance · IRWD
-
Q3 Results Confirmed in 10-Q
Revenue of $133.0 million versus $122.1 million a year ago, net income of $59.8 million and diluted EPS of $0.36, matching the 8-K filed the same morning.
-
Operating Cash Flow Corrected to $67.4M
The earnings press release overstated Q3 cash from operations at $130.8 million; the correct figure is $67.4 million, and the release has been updated on the company website.
-
Cash Falls to $86.4M After Debt Paydown
Cash and equivalents were $86.4 million at September 30 versus $215.5 million at December 31, 2025, after repaying $200.0 million of 2026 Convertible Notes at maturity and $60.0 million on the revolver, which now carries $325.0 million.
-
Alkem Patent Suit Stays Generic Approval
A June 12, 2026 Paragraph IV notice from Alkem led to a July 2026 infringement suit by Ironwood and AbbVie, triggering an FDA stay on the ANDA until up to December 12, 2028.
Analysis · IRWD · Life Sciences
The headline numbers were already public: Q3 revenue of $133.0 million, net income of $59.8 million and a second consecutive guidance raise all hit the tape this morning via 8-K. What is new here is a correction. The earnings release overstated quarterly cash from operations at $130.8 million when the actual figure was $67.4 million, roughly half. That matters because Ironwood's cash balance is the number investors use to judge how comfortably it can carry $325.0 million of revolver debt and fund the apraglutide STARS-2 trial toward a 2029 filing. Cash and equivalents stood at $86.4 million at September 30, down from $215.5 million at year-end after the $200.0 million convertible notes were repaid at maturity in June and $60.0 million came off the revolver. The filing also puts the Alkem Paragraph IV challenge on the record: a June 2026 notice and a July 2026 suit that stays FDA approval of that generic LINZESS ANDA until up to December 12, 2028.
How filings like this one have moved
In the 30 days to Nov 17, 2026, 38% of the 3791 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was 0.00%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, IRWD was trading at $4.04 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $665.9M. The 52-week trading range was $1.88 to $5.78. This filing was assessed with neutral market sentiment and an importance score of 7 out of 10.